


# Immunoglobulin Replacement Therapy is Critical and Cost-Effective in Increasing Life Expectancy and Quality of Life in Patients Suffering from Common Variable Immunodeficiency (CVID): A Health-Economic Assessment

This paper offers a health economic model to estimate the value of treatment with immunoglobulin replacement therapy (IgGRT) for CVID patients. Several important findings should be considered:

## COST-EFFECTIVENESS



Ig therapy is cost effective; **THE BENEFITS OUTWEIGH THE TREATMENT COSTS.**



World Health Organization

Considering World Health Organization guidelines, **IMMUNOGLOBULIN REPLACEMENT THERAPY** for CVID is **HIGHLY COST-EFFECTIVE.**

## VALUE




The **EARLIER A PATIENT** is **DIAGNOSED** and treatment begins, the more likely patients' lives will be impacted positively, resulting in **LARGER SOCIETY-WIDE BENEFITS.**



CVID patients treated with appropriate doses of IgGRT can expect to **LIVE 17 YEARS LONGER** than if they had little or no treatment.

## AWARENESS

Plasma is the essential starting material needed to manufacture therapies for people with CVID. Therefore, **PLASMA DONATION SHOULD BE ENCOURAGED.**



**RAISING AWARENESS IS KEY.**

**IT IS IMPORTANT FOR COMPETENT AUTHORITIES AND PAYERS TO RECOGNIZE THE VALUE OF IG THERAPIES FOR PATIENTS WITH CVID.**

